Canaccord Genuity Maintains Buy on Cartesian Therapeutics, Raises Price Target to $43
Canaccord Genuity Maintains Buy on Cartesian Therapeutics, Raises Price Target to $43
Canaccord Genuity維持對Cartesian Therapeutics的買入評級，並將目標價提高至43美元。
Canaccord Genuity analyst John Newman maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and raises the price target from $38 to $43.
Canaccord Genuity分析師約翰·紐曼認爲，Cartesian Therapeutics (納斯達克股票代碼：RNAC) 值得買入，並將目標價從38美元升至43美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。